AbbVie reported second-quarter 2026 revenue of $16.99 billion, exceeding analyst estimates of $16.79 billion and marking a 10.2% year-on-year increase. Adjusted earnings per share came in at $3.65, slightly above the $3.61 consensus. However, management lowered its full-year adjusted EPS guidance to $13.97 at the midpoint, a 1.5% reduction, citing anticipated dilution from the planned Apogee Therapeutics acquisition and ongoing pipeline investments. The immunology portfolio, led by SKYRIZI and RINVOQ, and the neuroscience segment each delivered growth above 20%, while oncology revenue declined due to competitive and pricing pressures on IMBRUVICA. The company also highlighted upcoming regulatory milestones, including new indications for SKYRIZI in Crohn's disease and RINVOQ in dermatology, as well as the launch of Tevapadon for Parkinson's disease.
AbbVie IncLowers full-year EPS guidance due to acquisition dilution and pipeline investments.
Apogee Therapeutics, Inc. Common StockAcquisition by AbbVie implies premium and strategic value.